Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation

FLT3-ITD measurable (minimal) residual disease (MRD) burden prior to allogeneic hematopoietic cell transplantation (HCT) is emerging as an important predictor of post-transplant relapse in patients with acute myeloid leukemia (AML). While there are three FLT3 inhibitors currently listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia as maintenance therapy options for those with FLT3-ITD mutated AML in remission post transplant, these recommendations do not incorporate MRD status, and no FLT3 inhibitors have been FDA approved for maintenance therapy in AML. The BMT-CTN 1506 MORPHO trial is actively investigating the efficacy of gilteritinib as post-transplant maintenance in the setting of detectable MRD.  It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Identify two highly sensitive techniques for measuring FLT3-ITD measurable (minimal) residual disease (MRD) in patients with acute myeloid leukemia.
  • Recognize the role of MRD as a predictor of post-transplant relapse in patients with acute myeloid leukemia.
  • Review the available clinical evidence supporting the use of FLT3 inhibitors as maintenance therapy post transplant.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; Coherus BioSciences; Dendreon Pharmaceuticals LLC; Eisai; Exact Sciences; Genentech, a member of the Roche Group; GRAIL, LLC; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Menarini-Stemline; Novartis; Novocure; Olympus Corporation of the Americas; Sanofi; Sirtex; and Taiho Oncology, Inc. Supported by independent educational grants from Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. Supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. Supported by a grant from Pfizer Inc. Supported by a medical education grant from Karyopharm Therapeutics. This project has been made possible in part by a grant from Varian Medical Systems, a Siemens Healthineers company/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
06/15/2024
Course expires: 
03/01/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Annual Conference

James M. Foran, MD
Mayo Clinic Comprehensive Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

John W. Sweetenham, MD

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

James M. Foran, MD 
AbbVie, Inc.: Grant/Research Support 
Actinium Pharmaceuticals, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor 
BeiGene: Scientific Advisor
Celgene Corporation: Grant/Research Support
Chordia Therapeutics Inc.: Grant/Research Support
CTI BioPharma Corp.: Scientific Advisor
Daiichi-Sankyo Co.: Scientific Advisor
Disc Medicine: Grant/Research Support
LAVA Therapeutics: Scientific Advisor 
Novartis Pharmaceuticals Corporation: Grant/Research Support
Remix Therapeutics: Scientific Advisor 
Roivant/Hemavant: Grant/Research Support 
Stemline Therapeutics, Inc.: Grant/Research Support 
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP 
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-24-052-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing